FDA OKs Neurocrine’s opicapone for Parkinson’s; shares up 5% premarket

FDA OKs Neurocrine’s opicapone for Parkinson’s; shares up 5% premarket
The FDA approves' (NASDAQ:NBIX) Ongentys (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing " ... read more
Source: Bing NewsPublished on 2020-04-27